Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.52 |
| ▸ | CES2 | O00748 | 6/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL3918420 | 0.98 | FAAH (0.54) | FAAHCES2CES1MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL28128351 | 0.98 | FAAH (0.50) | FAAHCES2CES1MEN1CYP1A2 | |
| Decane SCHEMBL6353937 | 0.98 | FAAH (0.54) | FAAHCES2CES1MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL28015086 | 0.96 | FAAH (0.48) | FAAHCES2CES1MEN1CYP1A2 | |
| Heptane SCHEMBL7647372 | 0.94 | FAAH (0.50) | FAAHCES2CES1MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3273685 | 0.90 | FAAH (0.61) | FAAHCES2CES1MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL5238463 | 0.90 | FAAH (0.44) | FAAHCES2CES1MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL28562828 | 0.88 | FAAH (0.42) | FAAHCES2CES1MEN1CYP1A2 | |
| Octane SCHEMBL1696265 | 0.87 | FAAH (0.62) | FAAHCES2CES1MEN1CYP1A2 | |
| Decane SCHEMBL3416451 | 0.87 | FAAH (0.62) | FAAHCES2CES1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116429927-A | Method for analyzing content of enantiomer in N-formyl-L-leucine | 大邦(湖南)生物制药有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-116297921-A | Isomer detection method of tedizolid phosphate intermediate | 成都美域高制药有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-114324702-A | Isomer detection method of carfilzomib intermediate | 南京格亚医药科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-112557566-A | Method for detecting corresponding isomer of mitiglinide calcium intermediate S-benzylsuccinic acid | 江西济民可信药业有限公司 | 2021-03-26 | — | — | CN | claimed |
| CN-112461985-A | Method for detecting malic acid isomer | 四川太平洋药业有限责任公司 | 2021-03-09 | — | — | CN | claimed |
| CN-107688069-B | Method for detecting (1R,2R) -cyclohexane-1, 2-dimethanol | 顾世海 | 2020-11-03 | — | — | CN | claimed |
| CN-109142585-B | Method for detecting isomer of sodium pantothenate | 珠海润都制药股份有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-109142585-A | A kind of detection method of sodium pantothenate isomers | 珠海润都制药股份有限公司 | 2019-01-04 | — | — | CN | claimed |
| CN-104535673-B | A kind of method of HPLC separation determination rosuvastain calcium enantiomter | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2016-04-20 | — | — | CN | claimed |
| CN-104535673-A | Method for separating and measuring enantiomer of rosuvastatin calcium via HPLC | GUANGDONG HEC PHARMACEUTICAL | 2015-04-22 | — | — | CN | claimed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| CN-118222650-A | Method for synthesizing itramod through asymmetric esterification | 安徽艾立德制药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117451900-A | Analysis method of threonine protected amino acid | 苏州正济药业有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117430547-A | Preparation method of single enantiomer of tetrahydrocyclopenta [ b ] indol-3-yl acetic acid and derivative thereof | 安徽艾立德制药有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-116769687-A | Recombinant escherichia coli for producing L-phenyllactic acid as well as construction method and application thereof | 大邦(湖南)生物制药有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-0700395-B1 | INDOLE DERIVATIVES AS STEROID 5-ALPHA-REDUCTASE INHIBITORS | PFIZER LTD (GB) | 1997-06-11 | — | — | EP | disclosed |
| EP-0700395-A1 | INDOLE DERIVATIVES AS STEROID 5-g(a)-REDUCTASE INHIBITORS | PFIZER LTD (GB) | 1996-03-13 | — | — | EP | disclosed |
| EP-0671975-A1 | CHIRAL ADSORBENTS AND PREPARATION THEREOF AS WELL AS COMPOUNDS ON WHICH THE ADSORBENTS ARE BASED AND PREPARATION OF THESE COMPOUNDS | Eka Chemicals AB (SE) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994027990-A1 | INDOLE DERIVATIVES AS STEROID 5α-REDUCTASE INHIBITORS | PFIZER LIMITED (GB) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994012275-A1 | CHIRAL ADSORBENTS AND PREPARATION THEREOF AS WELL AS COMPOUNDS ON WHICH THE ADSORBENTS ARE BASED AND PREPARATION OF THESE COMPOUNDS | EKA NOBEL AB (SE) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | FAAH 3374/4885CES2 2305/4885CES1 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.